Sources
End-of-wear patient reports with 99% physician agreement.1
- 99% of physicians agree with the comprehensive final patient report. Based on a review of all online Zio XT and AT final patient reports. Data on file. iRhythm Technologies, 2021.
MKT1514.01
MKT1516.01
Patients who wear Zio XT and Zio AT ambulatory cardiac monitors demonstrate 98% compliance with prescribed wear times. 1-3
- Data on file. iRhythm Technologies, 2021-2022.
MKT1530.01
The Zio service provides highly accurate data cardiologists trust.1
- Data on file. iRhythm Technologies, 2022-2023.
MKT1523.01
Patients demonstrate a 99% compliance with prescribed wear times using Zio monitor.1
- Data on file. iRhythm Technologies, 2022.
MKT1531.01
Patients who wear the Zio® monitor demonstrate a 99% compliance rate with prescribed wear times.1
- Data on file. iRhythm Technologies, 2022.
MKT1708.01
Compared to Zio LTCM service, Holter monitoring services were 1.35 times more likely to result in a retest and 50% less likely to detect a specified arrhythmia. 1-4
CAMELOT is the first and largest real-world evidence study of diagnostic-naive Medicare beneficiaries managed with external cardiac monitoring services. 1-4
- Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25-34. Accessed January 2, 2024. https://doi.org/10.1016/j.ahj.2023.12.002
- A specified arrhythmia refers to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.
- Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.
- Zio LTCM service refers to Zio XT and Zio monitor service.
MKT1528.01
Zio LTCM service was 2x as likely to result in a specified arrhythmia diagnosis, compared to Holter monitoring services, according to the CAMELOT study. 1-4
CAMELOT is the first and largest real-world evidence study of diagnostic-naive Medicare beneficiaries managed with external cardiac monitoring services. 1-4
- Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25-34. Accessed January 2, 2024. https://doi.org/10.1016/j.ahj.2023.12.002
- A specified arrhythmia refers to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.
- Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.
- Zio LTCM service refers to Zio XT and Zio monitor service.
MKT1527.01
Zio LTCM service had a 72% higher likelihood of a specified arrhythmia diagnosis, compared to AEM services, according to the CAMELOT study. 1-4
- 1. Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25-34. Accessed January 2, 2024. https://doi.org/10.1016/j.ahj.2023.12.002
- A specified arrhythmia refers to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.
- Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.
- Zio LTCM service refers to Zio XT and Zio monitor service.
MKT1526.01
MKT1529.01
Zio LTCM service was associated with the highest yield of specified arrhythmia diagnosis and the lowest likelihood of repeat testing. 1-4
Highest diagnostic yield, lowest retest likelihood. 1-4
CAMELOT is the first and largest study of its kind. 1-4
- Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25-34. Accessed January 2, 2024. https://doi.org/10.1016/j.ahj.2023.12.002
- A specified arrhythmia refers to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.
- Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.
- Zio LTCM service refers to Zio XT and Zio monitor service.
MKT1525.01
Zio LTCM service was 30% more likely than other LTCM services to detect a specified arrhythmia. 1-4
- Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25-34. Accessed January 2, 2024. https://doi.org/10.1016/j.ahj.2023.12.002
- A specified arrhythmia refers to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.
- Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.
- Zio LTCM service refers to Zio XT and Zio monitor service
MKT1524.01
MKT1529.01
MKT1707.01
Compared to Zio LTCM service, other LTCM services were 3.66x more likely to result in a retest, according to the CAMELOT study.1-4
- Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25-34. Accessed January 2, 2024. https://doi.org/10.1016/j.ahj.2023.12.002
- A specified arrhythmia refers to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.
- Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.
- Zio LTCM service refers to Zio XT and Zio monitor service.
MKT1495.01
Introducing the next-generation Zio® monitor, it’s smaller, lighter, and thinner.1
Introducing the new Zio® monitor, it’s smaller, lighter, and thinner. 1
- Data on file. iRhythm Technologies, 2023. Compared to previous generation.
MKT1601.01
Introducing the new Zio® monitor, it's small and comfortable for patients to wear.1,2
- Zio monitor Instructions for Use. iRhythm Technologies, 2023.
- Data on file. iRhythm Technologies, 2022.
MKT1710.01
According to a new study, Zio LTCM service had the highest yield of specified arrhythmia diagnosis and the lowest likelihood of repeat testing compared to all other monitoring services.1-4
- Reynolds et al. Comparative effectiveness of ambulatory monitors for arrhythmia diagnosis: A retrospective analysis of Medicare beneficiaries managed with ambulatory cardiac monitors between 2017 and 2019. Accepted for ACC.23 presentation, presented at New Orleans, LA.
- Specified arrhythmias defined by Hierarchical Condition Categories (HCC) 96.
- Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.
- Zio LTCM service refers to Zio XT and Zio monitor service.
MKT1529.01
Manage ambulatory cardiac monitoring through an EHR connection with full end-to-end data encryption.1
- The end-of-wear report data that is sent to EHR systems is limited to the fields found on the front page of the end-of-wear report.
MKT1706.01
Zio® LTCM service can streamline the patient journey with the lowest average ED and inpatient hospital utilization.1-3
- Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25-34. Accessed January 2, 2024. https://doi.org/10.1016/j.ahj.2023.12.002
- Claims Documentation excel sheet demonstrates the lowest average emergency department and inpatient hospital utilization.
MKT1705.01
Use the ZioSuite® portal and mobile app to interpret reports and efficiently manage patients.1
- This graphic is intended to be a general depiction to represent ZioSuite®. The patient names are fictional for demonstration purposes.
MKT1711.01
A Cardiac Monitoring Program can help you proactively identify irregular heart rhythms and improve patient outcomes while reducing costs.1
- Directional and potential outcome based upon modeling using iRhythm's mSToPS Calculator. iRhythm Technologies, 2023.
CUR0015.01
Undetected arrhythmia can significantly impact healthcare resource utilization, including emergency department visits and inpatient stays. Understanding these connections is critical for managing PMP savings effectively. 1,2
- Rozen et al. Emergency Department Visits for Atrial Fibrillation in the United States: Trends in Admission Rates and Economic Burden From 2007 to 2014. Journal of the American Heart Association. 2018;7(15). doi:https://doi.org/10.1161/jaha.118.009024
- Coyne et al. Assessing the direct costs of treating nonvalvular atrial fibrilation in the United States. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2006;9(5):348-356.doi:https://doi.org/10.1111/j.1524-4733.2006.00124X
CUR0018.01
Undetected cardiac arrythmias can drive emergency department visits and hospitalizations, impacting healthcare resource utilization.
- Turakhia et al. Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States. Clinical Cardiology. 2023;46(5):484-493. doi:https://doi.org/10.1002/clc.23983
- Coyne et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2006;9(5):348-356. doi:https://doi.org/10.1111/j.1524-4733.2006.00124.x
- Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25-34. Accessed January 2, 2024. https://doi.org/10.1016/j.ahj.2023.12.002
- Data on file. iRhythm Technologies, 2023.
CUR0020.01
iRhythm empowers primary care groups to proactively detect and manage Afib and other arrythmias, which may lead to reduced hospitalizations, drive down costs, and improve patient outcomes.1-3
- Turakhia et al. Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States. Clinical Cardiology. 2023;46(5):484-493. doi:https://doi.org/10.1002/clc.23983
- Coyne et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2006;9(5):348-356. doi:https://doi.org/10.1111/j.1524-4733.2006.00124.x
- Directional and potential outcome based upon modeling using iRhythm's mSToPS Calculator. iRhythm Technologies, 2023.
CUR0021.01
WEB0055.01